BridgeMD
New treatment option for Thymoma
Official title Glucocorticoids Combined With Concurrent Chemoradiotherapy for Unresectable Thymoma
ClinicalTrials.gov ID: NCT06730308
What this study is testing
What is Concurrent chemotherapy?
Concurrent chemotherapy is an investigational medicine, given as an once-weekly, being studied as a potential treatment for thymoma.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This study aims to assess the efficacy of methylprednisolone combined with concurrent chemoradiotherapy in treating unresectable or recurrent thymoma.
- Phase 2: a mid-size study of how well it works
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 75
You may be able to join if
- Histologically confirmed type AB or B1-3 thymoma.
- Measurable Disease: Patients must have measurable disease as defined by RECIST (Response Evaluation Criteria in Solid Tumors).
- Unresectable or recurrent thymoma, with the tumor confined to the chest and neck area.
- Between the ages of 18 and 70 years, regardless of sex.
- Eastern Cooperative Oncology Group performance status of 0 or 1.
You likely can't join if
- Contraindications to Methylprednisolone.
- History of or Concurrent Malignancy.
- Active infection, myocardial infarction within the last 6 months or symptomatic heart disease.
- Pregnant or Lactating Women.
- Bleeding Disorders.
- Recent Participation in Other Clinical Trials.
See the full eligibility criteria
- Histologically confirmed type AB or B1-3 thymoma.
- Measurable Disease: Patients must have measurable disease as defined by RECIST (Response Evaluation Criteria in Solid Tumors).
- Unresectable or recurrent thymoma, with the tumor confined to the chest and neck area.
- Between the ages of 18 and 70 years, regardless of sex.
- Eastern Cooperative Oncology Group performance status of 0 or 1.
- No prior chest radiation.
- Adequate organ Functions.
- Written informed consent obtained.
- Contraindications to Methylprednisolone.
- History of or Concurrent Malignancy.
- Active infection, myocardial infarction within the last 6 months or symptomatic heart disease.
- Pregnant or Lactating Women.
- Bleeding Disorders.
- Recent Participation in Other Clinical Trials.
- Drug Abuse or Severe Alcoholism.
- Uncontrolled Seizures or Mental Disorders.
- Severe Allergies or Specific Sensitivities.
The study team makes the final eligibility decision.
Where it's taking place
- Guanzhou, Guangdong, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 75 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Guanzhou, Guangdong, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.